If you get a partnership in DKD, why bother waisting money on a FSGS study? How is fsgs attractive if youve priced the drug for DKD?
Ann: Dimerix Plans for Next Study in Diabetic Kidney Disease, page-58
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
39.5¢ |
Change
0.015(3.95%) |
Mkt cap ! $220.0M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 40.5¢ | 37.0¢ | $863.2K | 2.230M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 56796 | 39.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.5¢ | 15592 | 1 |
View Market Depth
| Last trade - 15.59pm 08/10/2024 (20 minute delay) ? |
| DXB (ASX) Chart |